455 related articles for article (PubMed ID: 27068764)
1. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
2. Regulation of advanced therapy medicinal products in Europe and the role of academia.
Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
[TBL] [Abstract][Full Text] [Related]
3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
4. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
[TBL] [Abstract][Full Text] [Related]
5. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
6. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
[TBL] [Abstract][Full Text] [Related]
7. Advanced Therapy Medicinal Products and the Changing Role of Academia.
Priesner C; Hildebrandt M
Transfus Med Hemother; 2022 Jun; 49(3):158-162. PubMed ID: 35813600
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand.
Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P
Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851
[TBL] [Abstract][Full Text] [Related]
9. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
Bakopoulou A
J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products.
Horan A; Warreth S; Hervig T; Waters A
Cytotherapy; 2024 May; 26(5):524-530. PubMed ID: 38441513
[TBL] [Abstract][Full Text] [Related]
11. An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impact.
Hills A; Awigena-Cook J; Genenz K; Ostertag M; Butler S; Eggimann AV; Hubert A
Cytotherapy; 2020 Dec; 22(12):772-779.e1. PubMed ID: 33046395
[TBL] [Abstract][Full Text] [Related]
12. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
[TBL] [Abstract][Full Text] [Related]
13. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
Beattie S;
Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
[TBL] [Abstract][Full Text] [Related]
14. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
15. From the Integrity of Potency Assays to Safe Clinical Intervention: Legal Perspectives.
Roslin W; Mansnérus J
Adv Exp Med Biol; 2023; 1420():151-163. PubMed ID: 37258789
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
17. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
[TBL] [Abstract][Full Text] [Related]
18. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
[TBL] [Abstract][Full Text] [Related]
19. The advanced therapy classification procedure. Overview of experience gained so far.
Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
[TBL] [Abstract][Full Text] [Related]
20. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
